Abstract
At present, there are no antifungal vaccines available for the numerous people — in particular, immunocompromised individuals — who are at risk of infection with opportunistic fungal pathogens. However, new hope for the development of an effective vaccine has been provided by data published in The Journal of Experimental Medicine that indicate that immunization with the β-glucan laminarin conjugated to the diphtheria toxoid CRM197 protects mice from infection with Candida albicans and Aspergillus fumigatus.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
